If an experimental vaccine, using a novel TLR4 agonist adjuvant, fails to produce lasting protection, which mechanism is most likely responsible?

💡 Explanation

TLR4 agonists enhance antigen presentation and co-stimulation to B cells, which directly drives affinity maturation. Insufficient affinity maturation of B cells would cause a weaker, shorter-lived antibody response, because the B cells wouldn't have been optimized by somatic hypermutation; therefore, the vaccine would fail to provide lasting protection, rather than other inflammatory issues.

• Which outcome reduces vitamin K bioavailability, when long-term antibiotic use suppresses colonic bacteria?
• Why does hypokalemia (low potassium) in nervous tissue impair signal transmission?
• If a patient has a mutation that disables thromboxane production in platelets, which consequence follows during vascular injury?
• Why does intense exercise cause muscle fatigue faster in fast-twitch muscle fibers compared to slow-twitch fibers?
• Which skin response occurs given sustained tactile stress?
• Why does skin tanning in response to UV radiation differ significantly among individuals with varying levels of constitutive melanin?